tbuckley/cabot-search huggingface dataset:
12(S)-HETE mediates diabetes-induced endothelial dysfunction by activating intracellular endothelial cell TRPV1
Authors: Mandy Otto, Clarissa Bucher, Wantao Liu, Melanie Müller, Tobias Schmidt, Marina Kardell, Marvin Noel Driessen, Jan Rossaint, Eric R. Gross, Nana-Maria Wagner
Journal: Journal of Clinical Investigation (2020)

Patients with diabetes develop endothelial dysfunction shortly after diabetes onset that progresses to vascular disease underlying the majority of diabetes-associated comorbidities. Increased lipid peroxidation, mitochondrial calcium overload, and mitochondrial dysfunction are characteristics of dysfunctional endothelial cells in diabetic patients. We here identified that targeting the lipid peroxidation product 12(S)-hydroxyeicosatetraenoic acid-induced [12(S)-HETE-induced] activation of the intracellularly located cation channel transient receptor potential vanilloid 1 (TRPV1) in endothelial cells is a means to causally control early-stage vascular disease in type I diabetic mice. Mice with an inducible, endothelium-specific 12/15-lipoxygenase (12/15Lo) knockout were protected similarly to TRPV1-knockout mice from type 1 diabetes-induced endothelial dysfunction and impaired vascular regeneration following arterial injury. Both 12(S)-HETE in concentrations found in diabetic patients and TRPV1 agonists triggered mitochondrial calcium influx and mitochondrial dysfunction in endothelial cells, and 12(S)-HETE effects were absent in endothelial cells from TRPV1-knockout mice. As a therapeutic consequence, we found that a peptide targeting 12(S)-HETE-induced TRPV1 interaction at the TRPV1 TRP box ameliorated diabetes-induced endothelial dysfunction and augmented vascular regeneration in diabetic mice. Our findings suggest that pharmacological targeting of increased endothelial lipid peroxidation can attenuate diabetes-induced comorbidities related to vascular disease.
Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents
Authors: Carsten Riether, Thomas Pabst, Sabine Höpner, Ulrike Bacher, Magdalena Hinterbrandner, Yara Banz, Rouven Müller, Markus G. Manz, Walid H. Gharib, David Francisco, Remy Bruggmann, Luc van Rompaey, Mahan Moshir, Tim Delahaye, Domenica Gandini, Ellen Erzeel, Anna Hultberg, Samson Fung, Hans de Haard, Nicolas Leupin, Adrian F. Ochsenbein
Journal: Nature Medicine (2020)
Ending the Diagnostic Odyssey—Is Whole-Genome Sequencing the Answer?
Authors: Ann Chen Wu, Pamela McMahon, Christine Lu
Journal: JAMA Pediatrics (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Life-long dynamics of the swine gut microbiome and their implications in probiotics development and food safety
Authors: Ying Li, Xiaofan Wang, Xiu-qi Wang, Junjun Wang, Jiangchao Zhao
Journal: Gut Microbes (2020)

The swine gut microbiome has received remarkable attention in recent years given that pigs serve not only as important sources for animal-derived food but also as excellent biomedical models for human health. However, despite recent advances in the understanding of the swine gut microbiome, many important biological and ecological questions are still largely unanswered. In a recent study, we characterized the life-long dynamics of the swine gut microbiome from birth to market. We showed distinct shifts in gut microbiome structure along different growth stages mainly driven by diet. Here, we summarize these discoveries and provide additional data related to the core swine gut microbiome, probiotics development in the swine industry, and foodborne pathogens in the pork supply chain.
Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes
Authors: Alessandro Doria, Andrzej T. Galecki, Cathie Spino, Rodica Pop-Busui, David Z. Cherney, Ildiko Lingvay, Afshin Parsa, Peter Rossing, Ronald J. Sigal, Maryam Afkarian, Ronnie Aronson, M. Luiza Caramori, Jill P. Crandall, Ian H. de Boer, Thomas G. Elliott, Allison B. Goldfine, J. Sonya Haw, Irl B. Hirsch, Amy B. Karger, David M. Maahs, Janet B. McGill, Mark E. Molitch, Bruce A. Perkins, Sarit Polsky, Marlon Pragnell, William N. Robiner, Sylvia E. Rosas, Peter Senior, Katherine R. Tuttle, Guillermo E. Umpierrez, Amisha Wallia, Ruth S. Weinstock, Chunyi Wu, Michael Mauer
Journal: New England Journal of Medicine (2020)

Higher serum urate levels are associated with an increased risk of diabetic kidney disease. Lowering of the serum urate level with allopurinol may slow the decrease in the glomerular filtration rate (GFR) in persons with type 1 diabetes and early-to-moderate diabetic kidney disease.In a double-blind trial, we randomly assigned participants with type 1 diabetes, a serum urate level of at least 4.5 mg per deciliter, an estimated GFR of 40.0 to 99.9 ml per minute per 1.73 m2 of body-surface area, and evidence of diabetic kidney disease to receive allopurinol or placebo. The primary outcome was the baseline-adjusted GFR, as measured with iohexol, after 3 years plus a 2-month washout period. Secondary outcomes included the decrease in the iohexol-based GFR per year and the urinary albumin excretion rate after washout. Safety was also assessed.A total of 267 patients were assigned to receive allopurinol and 263 to receive placebo. The mean age was 51.1 years, the mean duration of diabetes 34.6 years, and the mean glycated hemoglobin level 8.2%. The mean baseline iohexol-based GFR was 68.7 ml per minute per 1.73 m2 in the allopurinol group and 67.3 ml per minute per 1.73 m2 in the placebo group. During the intervention period, the mean serum urate level decreased from 6.1 to 3.9 mg per deciliter with allopurinol and remained at 6.1 mg per deciliter with placebo. After washout, the between-group difference in the mean iohexol-based GFR was 0.001 ml per minute per 1.73 m2 (95% confidence interval [CI], -1.9 to 1.9; P = 0.99). The mean decrease in the iohexol-based GFR was -3.0 ml per minute per 1.73 m2 per year with allopurinol and -2.5 ml per minute per 1.73 m2 per year with placebo (between-group difference, -0.6 ml per minute per 1.73 m2 per year; 95% CI, -1.5 to 0.4). The mean urinary albumin excretion rate after washout was 40% (95% CI, 0 to 80) higher with allopurinol than with placebo. The frequency of serious adverse events was similar in the two groups.We found no evidence of clinically meaningful benefits of serum urate reduction with allopurinol on kidney outcomes among patients with type 1 diabetes and early-to-moderate diabetic kidney disease. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; PERL ClinicalTrials.gov number, NCT02017171.).
Insights From Senior Surgeons
Authors: Christopher S. Graffeo
Journal: JAMA Surgery (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Precision Calcium Imaging of Dense Neural Populations via a Cell-Body-Targeted Calcium Indicator
Authors: Or A. Shemesh, Changyang Linghu, Kiryl D. Piatkevich, Daniel Goodwin, Orhan Tunc Celiker, Howard J. Gritton, Michael F. Romano, Ruixuan Gao, Chih-Chieh (Jay) Yu, Hua-An Tseng, Seth Bensussen, Sujatha Narayan, Chao-Tsung Yang, Limor Freifeld, Cody A. Siciliano, Ishan Gupta, Joyce Wang, Nikita Pak, Young-Gyu Yoon, Jeremy F.P. Ullmann, Burcu Guner-Ataman, Habiba Noamany, Zoe R. Sheinkopf, Won Min Park, Shoh Asano, Amy E. Keating, James S. Trimmer, Jacob Reimer, Andreas S. Tolias, Mark F. Bear, Kay M. Tye, Xue Han, Misha B. Ahrens, Edward S. Boyden
Journal: Neuron (2020)
Self-expanding intra-annular versus commercially available transcatheter heart valves in high and extreme risk patients with severe aortic stenosis (PORTICO IDE): a randomised, controlled, non-inferiority trial
Authors: Raj R Makkar, Wen Cheng, Ron Waksman, Lowell F Satler, Tarun Chakravarty, Mark Groh, William Abernethy, Mark J Russo, David Heimansohn, James Hermiller, Stephen Worthley, Bassem Chehab, Mark Cunningham, Ray Matthews, Ravi K Ramana, Gerald Yong, Carlos E Ruiz, Chunguang Chen, Federico M Asch, Mamoo Nakamura, Hasan Jilaihawi, Rahul Sharma, Sung-Han Yoon, Augusto D Pichard, Samir Kapadia, Michael J Reardon, Deepak L Bhatt, Gregory P Fontana
Journal: The Lancet (2020)
Ethical challenges in nephrology: a call for action
Authors: Dominique E. Martin, David C. H. Harris, Vivekanand Jha, Luca Segantini, Richard A. Demme, Thu H. Le, Laura McCann, Jeff M. Sands, Gerard Vong, Paul Root Wolpe, Monica Fontana, Gerard M. London, Bert Vanderhaegen, Raymond Vanholder, Dominique E. Martin, David C. H. Harris, Vivekanand Jha, Luca Segantini, Richard A. Demme, Thu H. Le, Laura McCann, Jeff M. Sands, Gerard Vong, Paul Root Wolpe, Monica Fontana, Gerard M. London, Bert Vanderhaegen, Raymond Vanholder
Journal: Nature Reviews Nephrology (2020)
Albumin is a secret factor involved in multidirectional interactions among the serotoninergic, immune and endocrine systems that supervises the mechanism of CYP1A and CYP3A regulation in the liver
Authors: Martine Daujat-Chavanieu, Marta Kot
Journal: Pharmacology & Therapeutics (2020)

This review focuses on albumin, which is involved in multidirectional interactions among the immune, endocrine and serotoninergic systems and supervises the regulation of cytochrome P450 (CYP) isoforms under conditions of both normal liver function and liver insufficiency. Special attention is paid to albumin, thyroid hormones, testosterone and tryptophan hydroxylase in these interactions as well as their potential roles in liver regeneration. The association of these factors with inflammation and the modification of the mechanism of hepatic drug-metabolizing CYP isoform regulation are also presented because changes in the expression of CYP isoforms in the liver may result in subsequent changes to a marker substance used for testing CYP activity, thus providing a simple way to control the liver regeneration process or the dangerous stimulation of hepatocarcinogenesis.
Incidence and Onset of Severe Cardiac Events After Radiotherapy for Esophageal Cancer
Authors: Xin Wang, Nicolas L. Palaskas, Syed Wamique Yusuf, Jun-ichi Abe, Juan Lopez-Mattei, Jose Banchs, Gregory W. Gladish, Percy Lee, Zhongxing Liao, Anita Deswal, Steven H. Lin
Journal: Journal of Thoracic Oncology (2020)
Abstract TMIM-068: TARGETING ER STRESS RESPONSES TO UNLEASH THERAPEUTIC IMMUNITY AGAINST OVARIAN CANCER
Authors: Juan R Cubillos-Ruiz
Journal: Clinical Cancer Research (2019)

Abstract Harnessing the intrinsic ability of our immune system to eliminate malignant cells represents the most promising new anti-cancer strategy since the development of chemotherapy. While cancer immunotherapy has been designated a scientific breakthrough, tumor-induced immunosuppression still represents a major impediment to the success of this new approach in the vast majority of cancer patients. We found that ovarian cancer inhibits the development of protective anti-tumor immunity by inducing a state of continued “Endoplasmic Reticulum (ER) Stress” in tumor-associated dendritic cells (tDCs). Sustained activation of the IRE1-XBP1 arm of the ER stress response in DCs was necessary for the aggressive and accelerated progression of primary and metastatic ovarian cancers in various preclinical models of disease. Mechanistically, hyperactive XBP1 disrupted crucial metabolic pathways in tDCs and caused severe immune cell dysfunction at tumor sites. Accordingly, DC-specific XBP1 deletion or selective nanoparticle-mediated XBP1 silencing in tDCs restored their immunostimulatory activity in situ and extended survival by evoking protective T cell-mediated anti-tumor immunity. Our findings uncover a new regulatory role for XBP1-driven signaling in DCs of the tumor microenvironment and suggest that targeting aberrant ER stress responses may represent a new strategy to unleash protective immune responses against ovarian cancer. Citation Format: Juan R, Cubillos-Ruiz. TARGETING ER STRESS RESPONSES TO UNLEASH THERAPEUTIC IMMUNITY AGAINST OVARIAN CANCER [abstract]. In: Proceedings of the 12th Biennial Ovarian Cancer Research Symposium; Sep 13-15, 2018; Seattle, WA. Philadelphia (PA): AACR; Clin Cancer Res 2019;25(22 Suppl):Abstract nr TMIM-068.
Explaining the Rationale of Deep Learning Glaucoma Decisions with Adversarial Examples
Authors: Jooyoung Chang, Jinho Lee, Ahnul Ha, Young Soo Han, Eunoo Bak, Seulggie Choi, Jae Moon Yun, Uk Kang, Il Hyung Shin, Joo Young Shin, Taehoon Ko, Ye Seul Bae, Baek-Lok Oh, Ki Ho Park, Sang Min Park
Journal: Ophthalmology (2020)
Vulnerable children were harmed by charity’s “systemic” failures, inquiry finds
Authors: Clare Dyer
Journal: BMJ (2020)

Serious mismanagement and systemic failures of governance at the Royal National Institute of Blind People (RNIB) harmed some children in its care and exposed others to undue risk, an inquiry by the charity regulator has concluded.1

The report by the Charity Commission for England and Wales declared, “The commission considers elements of the failings identified by the inquiry, and the associated reviews, as constituting misconduct and collectively, as serious mismanagement in the administration of the charity.”

The inquiry could be characterised as “lifting the lid on a metaphorical can of worms,” the regulator said. Much of its report focuses on failings at the RNIB Pears Centre in Coventry, a school and children’s …
A novel TLX1-driven T-ALL zebrafish model: comparative genomic analysis with other leukemia models
Authors: Siebe Loontiens, Suzanne Vanhauwaert, Lisa Depestel, Givani Dewyn, Wouter Van Loocke, Finola E. Moore, Elaine G. Garcia, Lance Batchelor, Chiara Borga, Barbara Squiban, Megan Malone-Perez, Pieter-Jan Volders, Volodimir Olexiouk, Pieter Van Vlierberghe, David M. Langenau, J. Kimble Frazer, Kaat Durinck, Frank Speleman
Journal: Leukemia (2020)
Thiazide diuretics and the risk of hip fracture. Results from the Framingham Study
Authors: D. T. Felson
Journal: JAMA (1991)

Thiazide diuretics may preserve bone mass and prevent elderly women's osteopenic fractures, but studies have not distinguished between thiazide preparations or examined former users. We performed a case-control study looking at thiazide use and subsequent hip fracture in postmenopausal female members of the Framingham Study cohort. Cases who had experienced a first hip fracture (n = 176) were compared with age-matched controls (n = 672). Results showed a modest protective effect of any recent thiazide use (not significant). However, recent pure thiazide users experienced significant protection against fracture (adjusted odds ratio, 0.31; 95% confidence interval, 0.11 to 0.88), whereas recent users of combination drugs containing thiazides experienced no protection (adjusted odds ratio, 1.16; 95% confidence interval, 0.44 to 3.05). Combination drugs generally contained only 25 mg of hydrochlorothiazide, suggesting that the small amount of thiazide was insufficient to preserve bone mass. Former thiazide users were not protected against fracture. In sum, recent pure thiazide use in women protects against hip fracture. (JAMA. 1991;265:370-373)
Bedside Evaluation of Pulmonary Embolism by Saline Contrast Electrical Impedance Tomography Method: A Prospective Observational Study
Authors: Huaiwu He, Yi Chi, Yun Long, Siyi Yuan, Rui Zhang, Inéz Frerichs, Knut Möller, Feng Fu, Zhanqi Zhao
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

The electrical impedance tomography (EIT), a noninvasive, radiationfree, bedside lung imaging method, has gained attention in the diagnosis of acute respiratory failure (ARF), pleural effusion, and pneumothorax (1, 2) and monitoring of regional lung ventilation in mechanically ventilated patients (3, 4).Besides, EIT was proposed to quantitatively assess regional lung perfusion with saline bolus injection, which was validated in small animal studies (5,6).We demonstrated the clinical use of this method to detect acute pulmonary embolism (PE) in a recent case (7).To further confirm the feasibility of bedside detection of acute PE, we conducted a larger prospective observational clinical study using EIT.
The Effect of Inhaled Corticosteroid Withdrawal and Baseline Inhaled Treatment on Exacerbations in the IMPACT Study. A Randomized, Double-Blind, Multicenter Clinical Trial
Authors: MeiLan K. Han, Gerard J. Criner, Mark T. Dransfield, David M. G. Halpin, C. Elaine Jones, Sally Kilbride, Peter Lange, Sally Lettis, David A. Lipson, David A. Lomas, Neil Martin, Robert A. Wise, Dave Singh, Fernando J. Martinez
Journal: American Journal of Respiratory and Critical Care Medicine (2020)

Rationale: In the IMPACT (Informing the Pathway of Chronic Obstructive Pulmonary Disease Treatment) trial, fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) significantly reduced exacerbations compared with FF/VI or UMEC/VI in patients with symptomatic chronic obstructive pulmonary disease and a history of exacerbations.Objectives: To understand whether inhaled corticosteroid (ICS) withdrawal affected IMPACT results, given direct transition from prior maintenance medication to study medication at randomization.Methods: Exacerbations and change from baseline in trough FEV1 and St. George's Respiratory Questionnaire results were analyzed by prior ICS use. Exacerbations were also analyzed while excluding data from the first 30 days.Measurements and Main Results: FF/UMEC/VI significantly reduced the annual moderate/severe exacerbation rate compared with UMEC/VI in prior ICS users (29% reduction; P < 0.001), but only a numerical reduction was seen among prior ICS nonusers (12% reduction; P = 0.115). To minimize impact from ICS withdrawal, in an analysis excluding the first 30 days, FF/UMEC/VI continued to significantly reduce the annual on-treatment moderate/severe exacerbation rate (19%; P < 0.001) compared with UMEC/VI. The benefit of FF/UMEC/VI compared with UMEC/VI was seen for severe exacerbation rates, regardless of prior ICS use (prior ICS users, 35% reduction; P < 0.001; non-ICS users, 35% reduction; P = 0.018), and overall when excluding the first 30 days (29%; P < 0.001). Improvements from baseline with FF/UMEC/VI compared with UMEC/VI were also maintained throughout the study for both trough FEV1 and St. George's Respiratory Questionnaire, regardless of prior ICS use.Conclusions: These data support the important treatment effects of FF/UMEC/VI combination therapy on exacerbation reduction, lung function, and quality of life that do not appear to be related to abrupt ICS withdrawal.Clinical trial registered with www.clinicaltrials.gov (NCT02164513).
Multigenerational maternal obesity increases the incidence of HCC in offspring via miR-27a-3p
Authors: Yu Sun, Qing Wang, Yu Zhang, Mengyuan Geng, Yujuan Wei, Yanrui Liu, Shanshan Liu, Robert B. Petersen, Junqiu Yue, Kun Huang, Ling Zheng
Journal: Journal of Hepatology (2020)
Macrophage HIF-1α Is an Independent Prognostic Indicator in Kidney Cancer
Authors: Sophie J. Cowman, Daniel G. Fuja, Xian-De Liu, Rebecca S. Slack Tidwell, Neelima Kandula, Deepika Sirohi, Archana M. Agarwal, Lyska L. Emerson, Sheryl R. Tripp, Jeffrey S. Mohlman, Miekan Stonhill, Guillermina Garcia, Christopher J. Conley, Adam A. Olalde, Timothy Sargis, Adela Ramirez-Torres, Jose A. Karam, Christopher G. Wood, Kanishka Sircar, Pheroze Tamboli, Kenneth Boucher, Benjamin Maughan, Benjamin T. Spike, Thai H. Ho, Neeraj Agarwal, Eric Jonasch, Mei Yee Koh
Journal: Clinical Cancer Research (2020)

Abstract Purpose: Clear cell renal cell carcinoma (ccRCC) is frequently associated with inactivation of the von Hippel–Lindau tumor suppressor, resulting in activation of HIF-1α and HIF-2α. The current paradigm, established using mechanistic cell-based studies, supports a tumor promoting role for HIF-2α, and a tumor suppressor role for HIF-1α. However, few studies have comprehensively examined the clinical relevance of this paradigm. Furthermore, the hypoxia-associated factor (HAF), which regulates the HIFs, has not been comprehensively evaluated in ccRCC. Experimental Design: To assess the involvement of HAF/HIFs in ccRCC, we analyzed their relationship to tumor grade/stage/outcome using tissue from 380 patients, and validated these associations using tissue from 72 additional patients and a further 57 patients treated with antiangiogenic therapy for associations with response. Further characterization was performed using single-cell mRNA sequencing (scRNA-seq), RNA-in situ hybridization (RNA-ISH), and IHC. Results: HIF-1α was primarily expressed in tumor-associated macrophages (TAMs), whereas HIF-2α and HAF were expressed primarily in tumor cells. TAM-associated HIF-1α was significantly associated with high tumor grade and increased metastasis and was independently associated with decreased overall survival. Furthermore, elevated TAM HIF-1α was significantly associated with resistance to antiangiogenic therapy. In contrast, high HAF or HIF-2α were associated with low grade, decreased metastasis, and increased overall survival. scRNA-seq, RNA-ISH, and Western blotting confirmed the expression of HIF-1α in M2-polarized CD163-expressing TAMs. Conclusions: These findings highlight a potential role of TAM HIF-1α in ccRCC progression and support the reevaluation of HIF-1α as a therapeutic target and marker of disease progression.
Bacterial and host determinants of cough aerosol culture positivity in patients with drug-resistant versus drug-susceptible tuberculosis
Authors: Grant Theron, Jason Limberis, Rouxjeane Venter, Liezel Smith, Elize Pietersen, Aliasgar Esmail, Greg Calligaro, Julian te Riele, Marianna de Kock, Paul van Helden, Tawanda Gumbo, Taane G. Clark, Kevin Fennelly, Robin Warren, Keertan Dheda
Journal: Nature Medicine (2020)
Strategies for the Prevention and Treatment of Iatrogenic Withdrawal from Opioids and Benzodiazepines in Critically Ill Neonates, Children and Adults: A Systematic Review of Clinical Studies
Authors: Barbara Sneyers, Marc-Alexandre Duceppe, Anne Julie Frenette, Lisa D. Burry, Philippe Rico, Annie Lavoie, Céline Gélinas, Sangeeta Mehta, Maryse Dagenais, David R. Williamson, Marc M. Perreault
Journal: Drugs (2020)